A share price of Kiniksa Pharmaceuticals International Plc [KNSA] is currently trading at $21.46, up 5.82%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The KNSA shares have gain 9.32% over the last week, with a monthly amount glided 7.95%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Kiniksa Pharmaceuticals International Plc [NASDAQ: KNSA] stock has seen the most recent analyst activity on September 13, 2024, when Jefferies initiated its Buy rating and assigned the stock a price target of $40. Previously, Wells Fargo started tracking the stock with Overweight rating on May 03, 2024, and set its price target to $34. On June 29, 2020, BofA Securities reiterated its Buy rating and revised its price target to $40 on the stock. BofA/Merrill started tracking the stock assigning a Buy rating and suggested a price target of $25 on April 01, 2020. Barclays initiated its recommendation with a Overweight and recommended $26 as its price target on March 11, 2019. Wedbush reiterated a Outperform rating for this stock on December 12, 2018, and upped its price target to $33. In a note dated June 19, 2018, JMP Securities initiated an Mkt Outperform rating and provided a target price of $33 on this stock.
Kiniksa Pharmaceuticals International Plc experienced fluctuations in its stock price throughout the past year between $16.56 and $28.15. Currently, Wall Street analysts expect the stock to reach $37.5 within the next 12 months. Kiniksa Pharmaceuticals International Plc [NASDAQ: KNSA] shares were valued at $21.46 at the most recent close of the market. An investor can expect a potential return of 74.74% based on the average KNSA price forecast.
Analyzing the KNSA fundamentals
Trailing Twelve Months sales for Kiniksa Pharmaceuticals International Plc [NASDAQ:KNSA] were 423.24M which represents 46.93% growth. Gross Profit Margin for this corporation currently stands at 0.86% with Operating Profit Margin at -0.11%, Pretax Profit Margin comes in at -0.09%, and Net Profit Margin reading is -0.1%. To continue investigating profitability, this company’s Return on Assets is posted at -0.07, Equity is -0.1 and Total Capital is -0.1. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 20.52 points at the first support level, and at 19.57 for the second support level. However, for the 1st resistance point, the stock is sitting at 22.32, and for the 2nd resistance point, it is at 23.17.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Kiniksa Pharmaceuticals International Plc [NASDAQ:KNSA] is 3.30. As well, the Quick Ratio is 3.04, while the Cash Ratio is 1.82. Considering the valuation of this stock, the price to sales ratio is 3.68, the price to book ratio is 3.55.
Transactions by insiders
Recent insider trading involved Tessari Eben, CHIEF OPERATING OFFICER, that happened on Feb 10 ’25 when 14000.0 shares were sold. Officer, Tessari Eben completed a deal on Feb 10 ’25 to buy 14000.0 shares. Meanwhile, CHIEF OPERATING OFFICER Tessari Eben sold 14000.0 shares on Jan 13 ’25.
